NHS ADHD Waiting Times in 2026: A Clear Guide to Assessment, Diagnosis & Right to Choose

In early 2026, NHS ADHD waiting times in England range from 2 to 7 years depending on your area. Right to Choose was previously a reliable route to shorter waits, but several Integrated Care Boards have now paused or capped referrals, making access less predictable. Shared care agreements — needed to transfer prescribing to GPs — are also increasingly being refused by practices.

If you visit your GP and request an ADHD assessment, you will typically be referred to your local NHS adult ADHD service. From there, the timeline depends heavily on where you live.

• Average NHS ADHD waiting time in England: 2-5 years in many areas
• Some regions report waits of over 7 years for adult ADHD assessments
• Many services have temporarily closed their waiting lists entirely
• Children's services are also significantly stretched, though typically shorter

These are not estimates - they are reported figures from NHS trusts and Freedom of Information requests. The variation across England is substantial, and postcode lottery remains a significant barrier to access.

Under the NHS Constitution, patients in England have the legal right to choose which provider carries out their first outpatient appointment - including ADHD assessments.

This means you can ask your GP to refer you to a qualified, NHS-approved provider that may have significantly shorter waiting times than your local service. The assessment is still funded by the NHS - you do not pay.

Right to Choose applies to consultant-led services and first outpatient appointments. It is a legal entitlement, not a discretionary benefit, although commissioning arrangements vary between Integrated Care Boards (ICBs). In 2025-2026, this variation has become a major issue — check your ICB's current position below.

For a full guide to using Right to Choose for ADHD, including current ICB restrictions, read our dedicated ADHD Right to Choose guide.

Right to Choose waiting times vary by provider and have grown substantially since early 2025 due to a major surge in referrals. While RTC remains a valuable pathway, it is no longer a guaranteed fast-track to assessment.

For current provider-level waiting times, see ADHD UK's Right to Choose waiting times tracker.

We credit ADHD UK for maintaining publicly accessible summaries of Right to Choose provider waiting times.

Since mid-2025, several Integrated Care Boards (ICBs) across England have issued "revised activity plans" that pause or cap new ADHD assessments — including those referred through Right to Choose providers. This is the single biggest change to the ADHD assessment landscape in recent years.

• At least nine NHS areas have been affected, with some pauses running until at least April 2026
• ICBs cite budget pressures and an unprecedented surge in ADHD referrals as justification
• In affected areas, GPs have been instructed not to process new Right to Choose referrals for ADHD, meaning patients are directed back to local waiting lists
• The legal status of these caps is actively disputed

Most notably, ADHD UK challenged Coventry and Warwickshire ICB's suspension of adult ADHD referrals for over-25s, arguing it breaches the NHS Constitution and is potentially age-discriminatory. This challenge has drawn significant attention to the legality of ICB-imposed RTC restrictions.

What this means for you: Before assuming Right to Choose is available in your area, check your local ICB's current position. You can do this by contacting your GP surgery directly, checking your ICB's website, or consulting ADHD UK's RTC tracker for provider-level status updates.

An ADHD assessment is a clinical evaluation carried out by a qualified healthcare professional - typically a psychiatrist, specialist nurse, or psychologist. The process usually includes:

• A detailed clinical interview covering your current symptoms, childhood history, and daily functioning
• Standardised rating scales and questionnaires (such as DIVA-5 or Conners' scales)
• Collateral information - often a questionnaire completed by someone who knew you as a child
• A review of other possible explanations for your symptoms (differential diagnosis)

Assessments are typically conducted remotely via video call, though some providers offer in-person appointments. The duration is usually 60-90 minutes.

For a more detailed breakdown, see our article on what happens during an ADHD assessment.

ADHD has historically been underdiagnosed in adults, and particularly in women. There are several reasons why the pathway to diagnosis can take longer for some groups:

• Women are more likely to present with inattentive-type ADHD, which is less visibly disruptive and more frequently overlooked
• Many women develop compensatory strategies that mask symptoms until later in life, often triggered by a life transition such as pregnancy, career change, or caring responsibilities
• ADHD symptoms in women are more frequently misattributed to anxiety, depression, or hormonal changes
• GPs may be less familiar with how ADHD presents in adults compared to children

This means that many adults - especially women - arrive at the referral stage having already experienced years of unrecognised difficulty. The systemic waiting times compound this further.

Receiving a diagnosis is not the end of the process. If medication is recommended, you will typically enter a titration period - during which your clinician adjusts the type and dosage to find what works best for you.

• Titration usually takes 4-12 weeks
• During this period, you may have regular check-ins with your prescriber (weekly or fortnightly)
• Some providers charge separately for medication management if done privately
• National medication shortages have caused further delays in recent years

This "hidden waiting list" after diagnosis is often not discussed upfront, and can add several months to the overall timeline.

Once your medication is stabilised, the goal is usually to transfer prescribing responsibility to your GP through a shared care agreement. This means your GP takes over repeat prescriptions and routine monitoring, while the specialist remains available for clinical advice.

In 2025-2026, shared care refusals have become widespread — not exceptional. Several Local Medical Committees (LMCs) and Primary Care Networks (PCNs) have issued formal guidance discouraging GPs from entering new shared care agreements for ADHD medication. Many practices now follow this as default policy, not as an individual clinical decision.

This affects patients diagnosed via Right to Choose providers and private providers alike. Without a shared care agreement, patients must continue paying for private prescriptions — or re-enter the NHS pathway from the beginning.

Critical advice: Ask about your GP practice's shared care policy before committing to a provider, not only after diagnosis. If your practice has a blanket policy against shared care for ADHD, this could significantly affect the long-term cost and sustainability of your treatment.

If your GP declines shared care, you can ask them to explain their reasoning in writing and escalate through your local Integrated Care Board (ICB).

A private ADHD assessment offers the shortest waiting time - often 1-4 weeks. However, going private introduces additional considerations:

• Assessment fees typically range from £800 to £1,500 or more
• Medication and titration are often charged separately
• Shared care with your GP is not guaranteed and may require negotiation
• Quality varies - ensure your provider is registered with an appropriate regulatory body

Private assessment can be a practical option for those who can afford it, but it is important to understand the ongoing costs beyond the initial appointment.

The table below summarises the key differences between the three main pathways to an ADHD assessment in England.